Translational Drug Development (TD2)
TD2 is a CRO providing drug development services ranging from preclinical research to regulatory consultation to full Phase I-III clinical trial execution for small/mid-sized biopharmaceutical companies. This integrative approach accelerates development of cancer therapies. We are laser-focused on oncology and our premier team has deep experience and understanding of precision drug development. This results in the timely selection of targeted patient populations and the rapid identification of clinically significant endpoints. Work with a team that believes in your research as much as you do.